Leukocyte Adhesion Deficiency Type II – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

LAD II also recognized as a congenital disorder of glycosylation IIc (CDG IIc), is a rare congenital condition that disrupts the adhesion cascade’s initial phase, specifically impeding selectin-mediated leukocyte tethering and rolling on the endothelium. Selectins adhere to glycoproteins or glycolipids adorned with fucosylated carbohydrate structures akin to sialyl Lewisx (sLex). LAD II leukocytes exhibit a near-complete lack of sLex expression, significantly impeding interactions with endothelial selectins and resulting in immunodeficiency. Furthermore, they do not express the H blood group antigen (Bombay phenotype) or the Lewis blood group antigens Lea and Leb, all of which are oligosaccharides containing a fucose unit, leading to the initial hypothesis that LAD II stems from a generalized defect in fucosylated structure biosynthesis. LAD II manifests with significantly elevated peripheral neutrophil counts, the cause of which remains elusive. One plausible explanation is the diminished migration of cells from the vasculature into tissues due to deficient selectin interactions. However, bone marrow leukocyte production increased in one patient, suggesting another potential cause for neutrophilia. Functionally, neutrophils in LAD II are deficient in rolling on endothelium and migrating into the skin, thus mechanistically contributing to the immunodeficiency seen in the condition. As of now, only seven cases of LAD II have been documented worldwide. Four patients of Arab descent were identified in Israel, residing in the same region, with three of them being distantly related. Additionally, a boy of Turkish heritage was diagnosed in Germany, and a boy of Brazilian origin was studied in the USA. The most recent case is a girl of Pakistani descent discovered in Scotland.

Thelansis’s “Leukocyte Adhesion Deficiency Type II Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Leukocyte Adhesion Deficiency Type II treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Leukocyte Adhesion Deficiency Type II across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Leukocyte Adhesion Deficiency Type II Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Leukocyte Adhesion Deficiency Type II – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Leukocyte Adhesion Deficiency Type II, Leukocyte Adhesion Deficiency Type II market outlook, Leukocyte Adhesion Deficiency Type II competitive landscape, Leukocyte Adhesion Deficiency Type II market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)